- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Hyperkalaemia |
|---|
|
| Prevention of hyperkaliaemia in chemotherapy |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Constipation. After rectal administration, especially in children: there is a risk of intestinal obstruction due to clumping of the resin, and of haematochezia in premature infants and neonates with a low birthweight.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Neonates (oral administration). Neonates of ≤ 28 weeks pregnancy or in reduced intestinal activity (oral and rectal administration).
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Watch out for obstipation. Check the plasma concentrations of sodium and potassium regularly. Rectal administration requires special care in low birthweight neonates and premature infants due to the risk of digestive haemorrhage or colon necrosis, especially in cases of excessive dosing or inadequate dilution.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Antidotes | ||
|---|---|---|
| V03AB27 | ||
| V03AB16 | ||
| V03AB24 | ||
| V03AB25 | ||
| V03AB33 | ||
| V03AB17 | ||
| V03AB15 | ||
| V03AB13 | ||
| V03AB19 | ||
| V03AB14 | ||
| V03AB06 | ||
| V03AB35 | ||
| Iron chelating agents | ||
|---|---|---|
| V03AC03 | ||
| V03AC02 | ||
| V03AC01 | ||
| Drugs for treatment of hyperkalemia and hyperphosphatemia | ||
|---|---|---|
| V03AE07 | ||
| V03AE01 | ||
| V03AE02 | ||
| Detoxifying agents for antineoplastic treatment | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| Drugs for treatment of hypoglycemia | ||
|---|---|---|
| V03AH01 | ||
| Other therapeutic products | ||
|---|---|---|
| V03AX03 | ||
| DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| OTHER THERAPEUTIC PRODUCTS | ||
|---|---|---|
| V03AX03 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Sanofi-Aventis Netherlands BV, SPC Resonium A (RVG 08071), www.cbg-meb.nl, Geraadpleegd 11 aug 2010, http://db.cbg-meb.nl/IB-teksten/h08071.pdf
- Kamps WA et al, Werkboek ondersteundende behandeling kinderoncologie, VU Uitgeverij, 2005
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
